--- title: "Theriva Biologics To Present VIRAGE Data; Stock Jumps" type: "News" locale: "en" url: "https://longbridge.com/en/news/283296122.md" description: "Theriva Biologics (TOVX) will present data from the VIRAGE study at the AACR Annual Meeting 2026, focusing on VCN-01's effectiveness in treating metastatic pancreatic cancer. The study shows improved outcomes for patients, including those with liver metastases. VCN-01, an oncolytic adenovirus, enhances chemotherapy access and immune response. Theriva plans a Phase 3 trial and a smaller study to explore extended dosing schedules. The stock price rose significantly, closing at $0.25 and jumping to $0.46 in overnight trading, reflecting investor optimism about the treatment's potential." datetime: "2026-04-20T05:10:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283296122.md) - [en](https://longbridge.com/en/news/283296122.md) - [zh-HK](https://longbridge.com/zh-HK/news/283296122.md) --- # Theriva Biologics To Present VIRAGE Data; Stock Jumps (RTTNews) - Theriva Biologics (TOVX) is scheduled to present additional subgroup analyses from the VIRAGE study today at the American Association for Cancer Research (AACR) Annual Meeting 2026, which evaluates VCN-01 in combination with gemcitabine and nab-paclitaxel in newly diagnosed metastatic pancreatic cancer patients. The data, to be shared in a poster presentation by Dr. Manuel Hidalgo of NYU Langone Health, highlight improved outcomes across multiple patient groups, including those with liver metastases. VCN-01, also known as zabilugene almadenorepvec, is a systemically administered oncolytic adenovirus designed to selectively replicate within tumor cells and degrade the tumor stroma- a barrier that often limits the effectiveness of cancer therapies. By breaking down this barrier, VCN-01 enhances chemotherapy access, increases tumor immunogenicity, and exposes cancer cells to the patient's immune system. Earlier clinical observations showed that patients receiving VCN-01 plus chemotherapy experienced longer response durations and improved survival compared to chemotherapy alone. Building on these findings, Theriva has aligned with both the FDA and EMA on plans for a pivotal Phase 3 trial to evaluate multiple dosing regimens of VCN-01 in the first-line metastatic regimens of VCN-01 in first-line metastatic PDAC. The company is also preparing a smaller study to test whether extended dosing schedules could further improve patient outcomes. Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of pancreatic cancers and is often diagnosed at advanced stages, leaving limited treatment options. With only a fraction of cases eligible for surgical resection, novel therapies like VCN-01 represent a critical area of research. Theriva's upcoming presentation at AACR 2026 reflects its continued commitment to advancing treatments in areas of high unmet need, with VCN-01 positioned as a promising candidate to reshape outcomes for patients facing one of the most aggressive forms of cancer. TOVX has traded between $0.16 and $1.50 over the past year. The stock closed Friday's trading (April 17, 2026) at $0.25, up 1.94%. During the overnight trading session, the stock rose further to $0.46, up 79.08%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [TOVX.US](https://longbridge.com/en/quote/TOVX.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md) ## Related News & Research - [Theriva Biologics doses first patient in VIRAGE2 Phase 2a trial of VCN-01 for metastatic pancreatic cancer](https://longbridge.com/en/news/295106175.md) - [HC Wainwright Starts Theriva (TOVX) at Buy on Undervalued Oncolytic Virus Platform and Advancing VCN-01 Pancreatic Cancer Program](https://longbridge.com/en/news/295697080.md) - [Theriva Biologics wins Spanish regulator clearance for VIRAGE2 VCN-01 pancreatic cancer trial](https://longbridge.com/en/news/291928699.md) - [Medicare is about to change a drug program that held down the cost of premiums. Here's what to know.](https://longbridge.com/en/news/294391519.md) - [Has the bull market shifted to biotech stocks?](https://longbridge.com/en/news/293077044.md)